V

Varian

Tech-enabled radiation oncology hardware and software

Global Health Economics Director - CCVP

Full-Time
$154.2k - $212k+ Commission
Expert
Bachelor's, MBA
Remote in USA
Remote
Finance & BankingCorporate Finance & FP&A
Company Historically Provides H1B Sponsorship

About the job

Requirements
  • An advanced degree in a health, business, or quantitative discipline with direct application to healthcare economics, finance, or outcomes measurement; alternatively, an MBA with 10+ years of progressive healthcare finance leadership within large, complex integrated delivery networks.
  • At least 8 years of progressive experience in strategic healthcare finance, health economics, or outcomes research, with director-level leadership scope, including ownership of multi-hundred-million-dollar profit-and-loss responsibilities, advising C-suite executives, and driving enterprise decision-making.
  • Demonstrated expertise building sophisticated financial models for complex oncology programs, including cost-per-case analyses, return-on-investment and pro forma models, multi-scenario forecasting, budget impact frameworks, and service line economics.
  • Proficiency in advanced Excel, business intelligence tools such as Power BI or Essbase (or equivalent), and data visualization.
  • Deep knowledge of U.S. healthcare economics and reimbursement, including Medicare and Medicaid, the Centers for Medicare & Medicaid Services, commercial payers, hospital value analysis committees, and integrated delivery network procurement processes.
  • Hands-on experience analyzing payer-mix impact, reimbursement variability, and revenue optimization across clinical programs.
  • Strong understanding of oncology care pathways and clinical and operational factors that drive financial performance, including radiation oncology economics, linear accelerator utilization, fraction volume, capital intensity, infusion economics, and specialty pharmacy.
  • A track record supporting large, complex strategic deals and partnerships with health-economic evidence and return-on-investment tools, including multi-year, multi-site program economics, capital investment justification, and performance modeling.
  • Ability to translate complex financial and clinical-economic data into clear narratives for C-suite stakeholders, including chief financial officers, chief medical officers, chief operating officers, and chief executive officers.
  • Ability to influence strategic decisions without direct authority across matrixed organizations.
  • Experience partnering with clinical and operational leadership on strategic planning, including scenario-based planning, service line growth strategy, access expansion, and efficiency initiatives.
  • International healthcare economics experience and cross-cultural stakeholder engagement.
Responsibilities
  • Develop and lead the multi-year Cancer Care Value Programs strategic and financial roadmap, aligning it with corporate growth, profitability, and market-expansion objectives.
  • Define, implement, and continuously refine a global key performance indicator framework measuring revenue growth and margin performance of program deals; customer value realization such as cost savings, throughput, and outcomes; market-access milestones such as coverage, reimbursement levels, and policy wins; and adoption and utilization rates of oncology solutions.
  • Establish standardized dashboards and monthly, quarterly, and annual reporting to track key performance indicators and provide actionable insights to executive leadership.
  • Partner with Finance to integrate key performance indicators into budgeting, forecasting, and long-range planning, aligning strategic objectives with financial outcomes.
  • Lead performance reviews of program partnerships, identify risks and opportunities, and implement corrective actions to optimize return on investment.
  • Build health-system-specific economic models and return-on-investment frameworks to support large-scale value partnership deals, including multi-year agreements with integrated delivery networks and government health authorities.
  • Design and oversee health economic models, including cost-effectiveness analyses, budget impact models, cost-comparison and total-cost-of-care analyses, and hospital-based health technology assessment models.
  • Define and track model-performance key performance indicators, including forecast accuracy against realized outcomes and model adoption by commercial teams.
  • Translate modeling outputs into quantifiable performance metrics that can be tracked after implementation to validate value delivery.
  • Partner with Clinical Research and Medical Affairs to design real-world evidence and outcomes studies aligned with payer and health technology assessment expectations.
  • Define measurable clinical, operational, and economic endpoints and incorporate them into longitudinal key performance indicator tracking frameworks.
  • Develop and oversee processes to monitor real-world performance against projected value hypotheses and feed findings into strategy and modeling.
  • Develop value narratives, economic tools, and payer-facing materials for program solutions such as radiation therapy and theranostics.
  • Ensure value propositions are supported by defined, trackable key performance indicators relevant to stakeholders, such as cost per patient, improved outcomes, and system-efficiency gains.
  • Partner with Global Commercial Marketing to integrate key-performance-indicator-driven value messaging into product launches and competitive positioning.
  • Support reimbursement strategy and coding initiatives, including Current Procedural Terminology and Ambulatory Payment Classification codes, in collaboration with Government Affairs on Centers for Medicare & Medicaid Services engagement and advocacy.
  • Define and monitor market-access key performance indicators, including coverage decisions, reimbursement levels, and policy-adoption timelines.
  • Track and report the financial and strategic impact of market-access wins on program performance.
  • Collaborate with Digital Health and AI teams to develop and validate outcomes evidence for AI-driven oncology solutions and workflow-optimization tools.
  • Inform data-driven key performance indicator tracking systems that use digital tools and analytics platforms to provide real-time performance insights.
  • Drive adoption of advanced analytics to enable predictive performance monitoring and continuous improvement of program offerings.
  • Serve as a strategic partner across functions, aligning goals, metrics, and performance tracking.
  • Lead governance forums to review key performance indicators, assess progress, and drive decision-making across global stakeholders.
  • Build a culture of data-driven accountability and performance management within the Cancer Care Value Programs organization.

About the company

Varian, part of Siemens Healthineers, focuses on oncology by providing integrated radiation oncology solutions that combine software, hardware, patient data, and care teams. Its offerings include treatment-planning software, radiation therapy machines, and data-management systems that work together to enable precise cancer treatments. The company differentiates itself through an integrated platform approach and services like Oncology-as-a-Service (OaaS), which lets healthcare providers adopt advanced radiation oncology with ongoing service support rather than large upfront investments. Varian serves healthcare providers such as hospitals and cancer centers, helping them deliver coordinated care and improve patient outcomes. Its goal is to reduce the fear of cancer by using data and technology to support clinicians in delivering effective treatments.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

1948

Get referred to Varian

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ARPA-H awarded Varian up to $60 million in April 2026 for FLASH-RT.
  • FDA cleared TrueBeam for osteoarthritis in March 2026, opening a non-cancer market.
  • Telix collaboration and 2026 AI approvals expand Varian's clinical and software pipeline.

What critics are saying

  • RaySearch enabled online adaptive TrueBeam workflows in Belgium in May 2026, eroding software differentiation.
  • Elekta still attacks Varian's lead in adaptive radiotherapy and premium MR-guided care.
  • If FLASH and non-oncology bets fail by 2028, Varian becomes a commoditized linear-accelerator vendor.

What makes Varian unique

  • Siemens Healthineers gives Varian imaging, radiotherapy, and capital-sales integration globally.
  • Varian's 2026 CE-marked Eclipse AI contouring deepens workflow lock-in across planning.
  • TrueBeam, Halcyon, and Ethos create an installed-base moat hospitals rarely replace.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Holidays
  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Wellness Program
  • 401(k) Retirement Plan

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Varex Imaging Corporation
Sep 14th, 2026
About Us | Varex Imaging Corporation

We strive to help customers become world-class system suppliers by strengthening their competitiveness and enabling them to bring products to market faster

MEDQOR
Apr 30th, 2026
Siemens Healthineers secures $83M to develop photon Flash radiotherapy for cancer treatment

Siemens Healthineers has received up to $60 million from the US Advanced Research Projects Agency for Health to develop photon Flash radiotherapy, with the company contributing an additional $23 million, totalling $83 million over five years. Flash photon therapy delivers radiotherapy more than 100 times faster than current technologies, aiming to reduce side effects and improve healthy tissue sparing. Unlike proton and electron beam platforms, which face scalability challenges, photon beams are the standard of care for over 50% of cancer patients. The project will build on existing C-arm linear accelerators to enable broader clinical access. Siemens Healthineers aims to transition ultra-high dose rate radiotherapy from experimental treatment into global standard of care within the five-year timeframe.

Business Wire
Mar 19th, 2026
Varian TrueBeam gets FDA clearance for low-dose radiotherapy to treat osteoarthritis

Siemens Healthineers has received FDA 510(k) clearance for its Varian TrueBeam radiotherapy systems to treat medically refractory osteoarthritis in adults using low-dose radiation therapy. This marks the first expansion of Varian's radiotherapy platform beyond cancer care into chronic musculoskeletal conditions. Osteoarthritis affects over 33 million adults in the US and approximately 600 million globally. The clearance covers TrueBeam, TrueBeam STx, VitalBeam and Edge systems, offering patients with persistent pain a non-invasive outpatient treatment option that targets inflammation, reduces pain and improves joint function. The approval builds on Varian's previous regulatory clearances for non-oncological indications, including radiosurgery treatment for medically refractory essential tremor. The TrueBeam platform combines high-resolution imaging with precise dose control whilst maintaining streamlined clinical workflows.

AuntMinnieEurope.com
Dec 10th, 2025
Telix and Varian enter research collaboration

Telix and Varian enter research collaboration. Telix Pharmaceuticals and Siemens Healthineers' company Varian have agreed to develop novel clinical applications that combine Telix's theranostics products and Varian's external beam radiation therapy (EBRT) technology. The first area of focus will be in identifying opportunities to use Telix's prostate cancer PET imaging agents in selecting patients for EBRT, developing personalized treatment plans (particularly in the context of Varian's Ethos adaptive radiotherapy system), and monitoring responses to treatment, Telix said. The agreement supports both company-sponsored and investigator-led clinical studies. Varian is a key player in EBRT and working with the company will allow Telix to explore how theranostics can be used more effectively by radiation oncologists to enhance patient selection and deliver targeted treatment, Telix noted. I agree to receive marketing related digital communications about products, services, events and offers that may be relevant to my given user preferences and behavior. I agree to share my information with the sponsor. I have read and agree to the privacy policy & terms of service and wish to opt-in.

AuntMinnie.com
Mar 28th, 2025
Varian, Embolx sign image-guided microcatheter agreement

Siemens Healthineers company Varian has entered into a sales and marketing agreement with Embolx for its Sniper Balloon Occlusion Microcatheter.